Atieh Rahmati1, Ramin Shakeri1, Hooman Khademi1, Hossein Poutschi1, Akram Pourshams1, Arash Etemadi1,2, Masoud Khoshnia3, Amir Ali Sohrabpour1, Ali Aliasgari1, Elham Jafari1, Farhad Islami1,4, Shahryar Semnani3, Abdolsamad Gharravi1,3, Christian C Abnet2, Paul D P Pharoah5, Paul Brennan6, Paolo Boffetta7, Sanford M Dawsey2, Reza Malekzadeh1, Farin Kamangar1,8. 1. Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. 3. Golestan Research Center of Gastroenterology& Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran. 4. American Cancer Society, Atlanta, Georgia, USA. 5. Departments of Oncology and Public Health and Primary Care University of Cambridge, Cambridge, UK. 6. International Agency for Research on Cancer, Lyon, France. 7. The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 8. Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Recent studies have suggested that opium use may increase mortality from cancer and cardiovascular diseases. However, no comprehensive study of opium use and mortality from respiratory diseases has been published. We aimed to study the association between opium use and mortality from respiratory disease using prospectively collected data. METHODS: We used data from the Golestan Cohort Study, a prospective cohort study in northeastern Iran, with detailed, validated data on opium use and several other exposures. A total of 50 045 adults were enrolled from 2004 to 2008, and followed annually until June 2015, with a follow-up success rate of 99%. We used Cox proportional hazard regression models to evaluate the association between opium use and outcomes of interest. RESULTS: During the follow-up period, 331 deaths from respiratory disease were reported (85 due to respiratory malignancies and 246 due to non-malignant aetiologies). Opium use was associated with an increased risk of death from any respiratory disease (adjusted HR 95% CI 3.13 (2.42 to 4.04)). The association was dose-dependent with a HR of 3.84 (2.61 to 5.67) for the highest quintile of cumulative opium use versus never use (Ptrend<0.001). The HRs (95% CI) for the associations between opium use and malignant and non-malignant causes of respiratory mortality were 1.96 (1.18 to 3.25) and 3.71 (2.76 to 4.96), respectively. CONCLUSIONS: Long-term opium use is associated with increased mortality from both malignant and non-malignant respiratory diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: Recent studies have suggested that opium use may increase mortality from cancer and cardiovascular diseases. However, no comprehensive study of opium use and mortality from respiratory diseases has been published. We aimed to study the association between opium use and mortality from respiratory disease using prospectively collected data. METHODS: We used data from the Golestan Cohort Study, a prospective cohort study in northeastern Iran, with detailed, validated data on opium use and several other exposures. A total of 50 045 adults were enrolled from 2004 to 2008, and followed annually until June 2015, with a follow-up success rate of 99%. We used Cox proportional hazard regression models to evaluate the association between opium use and outcomes of interest. RESULTS: During the follow-up period, 331 deaths from respiratory disease were reported (85 due to respiratory malignancies and 246 due to non-malignant aetiologies). Opium use was associated with an increased risk of death from any respiratory disease (adjusted HR 95% CI 3.13 (2.42 to 4.04)). The association was dose-dependent with a HR of 3.84 (2.61 to 5.67) for the highest quintile of cumulative opium use versus never use (Ptrend<0.001). The HRs (95% CI) for the associations between opium use and malignant and non-malignant causes of respiratory mortality were 1.96 (1.18 to 3.25) and 3.71 (2.76 to 4.96), respectively. CONCLUSIONS: Long-term opium use is associated with increased mortality from both malignant and non-malignant respiratory diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Clinical Epidemiology; Lung Cancer; Tobacco and the lung
Authors: M Friesen; I K O'Neill; C Malaveille; L Garren; A Hautefeuille; J R Cabral; D Galendo; C Lasne; M Sala; I Chouroulinkov Journal: Mutat Res Date: 1985 Jun-Jul Impact factor: 2.433
Authors: C Malaveille; M Friesen; A M Camus; L Garren; A Hautefeuille; J C Béréziat; P Ghadirian; N E Day; H Bartsch Journal: Carcinogenesis Date: 1982 Impact factor: 4.944
Authors: Hooman Khademi; Reza Malekzadeh; Akram Pourshams; Elham Jafari; Rasool Salahi; Shahryar Semnani; Behrooz Abaie; Farhad Islami; Siavosh Nasseri-Moghaddam; Arash Etemadi; Graham Byrnes; Christian C Abnet; Sanford M Dawsey; Nicholas E Day; Paul D Pharoah; Paolo Boffetta; Paul Brennan; Farin Kamangar Journal: BMJ Date: 2012-04-17